🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Spain / NCT07288606
Active, not recruiting Not applicable

Analysising the Marginal Bone Loss, Torque and Implant Stability Placed in Bone and Tissue Level Dental Implants

NCT07288606 · tracked via the Priya Life Science Spain tracker
Phase
Not applicable
Started
2022-12-02
Last updated
2026-01-06

Condition(s) studied

Dental ImplantImplant Stability

Investigational drug(s) / intervention(s)

Dental implant placement

Dental implant placement: Surgical placement of Bone-level and Tissue-level dental implants.

Study summary

It is a prospective clinical study to compare two implants of the same brand of a similar design for implantation \[either at the bone tissue level or at the soft tissue level\], in order to evaluate the marginal bone loss of each dental implant in mm. 96 patients will be analyzed (an expected N of 48 per group, hoping to reach 100 implants per arm).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients of both sexes, over 18 years of age, who need dental implant placement for prosthetic rehabilitation. Whether partially or completely in both the maxilla and the mandible. * Patients with residual alveolar ridge with at least 8 mm of bone height and 4 mm of width. * Patients must have the ability to understand and decide when voluntarily signing the informed consent before carrying out any intervention related to the study. * Patients who, after being informed about the objectives and procedures of the research, agree will sign the informed consent form. And they are ready to carry out the different study visits. Exclusion Criteria: * Patients with uncontrolled systemic diseases (ASA ≥ III). * Patients who do not have 8mm bone height and/or 4mm width * Patients who require bone regeneration * Patients with severe periodontal disease or acute pericoronitis. * Pregnant and breastfeeding women. * Patients with Deficient or Inadequate Oral Hygiene. * Patients with severe bruxism. * Patients taking bisphosphonates or other antiresority medications. * Smoker of more than 10 cigarettes/day. * Patients with uncontrolled diabetes mellitus. * Psychiatric illnesses or unrealistic expectations. * Immunodepressed or immunocompromised patient.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Hospital Odontologic Barcelona L'Hospitalet de Llobregat

More University of Barcelona trials in Spain

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07288606 on ClinicalTrials.gov ↗ ← All trials in Spain